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Ribosome profiling at isoform level reveals
evolutionary conserved impacts of differential
splicing on the proteome
Marina Reixachs-Solé1,2, Jorge Ruiz-Orera3, M. Mar Albà 4,5,6 & Eduardo Eyras 1,2,4,5✉
The differential production of transcript isoforms from gene loci is a key cellular mechanism.
Yet, its impact in protein production remains an open question. Here, we describe ORQAS
(ORF quantification pipeline for alternative splicing), a pipeline for the translation quantifi-
cation of individual transcript isoforms using ribosome-protected mRNA fragments (ribo-
some profiling). We find evidence of translation for 40–50% of the expressed isoforms in
human and mouse, with 53% of the expressed genes having more than one translated
isoform in human, and 33% in mouse. Differential splicing analysis revealed that about 40%
of the splicing changes at RNA level are concordant with changes in translation. Furthermore,
orthologous cassette exons between human and mouse preserve the directionality of the
change, and are enriched in microexons in a comparison between glia and glioma. ORQAS
leverages ribosome profiling to uncover a widespread and evolutionarily conserved impact of
differential splicing on translation, particularly of microexon-containing isoforms.
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The alternative processing of transcribed genomic locithrough transcript initiation, splicing, and polyadenylationdetermines the repertoire of RNA molecules in cells1.
Differential production of transcript isoforms, especially through
the mechanism of alternative splicing, is crucial in multiple bio-
logical processes such as cell differentiation, acquisition of tissue-
specific functions, and DNA repair2–4, as well as in multiple
pathologies5–7. Although analysis of RNA-sequencing (RNA-seq)
data from multiple samples has indicated a large diversity of
transcript molecules8, genes express mostly one single isoform in
any given condition and this isoform may change across
conditions9,10.
Computational and in vitro studies have provided evidence
that a change in relative isoform abundances can lead to the
production of protein variants that impact the network of
protein–protein interactions in different contexts11–14. In con-
trast, quantitative proteomics of naturally occurring proteins has
identified much fewer protein variants than those predicted with
RNA sequencing15,16. Using state-of-the-art proteomics, it was
recently shown that splicing changes at the RNA level lead to
changes in the sequence and abundance of proteins produced,
although this was detected only for a limited number of tran-
scripts16. The difficulty in establishing a correspondence between
transcript and protein variation may be not only due to limita-
tions in current proteomics technologies, but also to the stability
and translation regulation of transcripts17,18. Despite the evidence
about its functional relevance3, it is still debated whether differ-
ential splicing leads to fundamentally different proteins and how
widespread this might be19–21. Of particular interest are micro-
exons, which can be as short as three nucleotides and carry out
conserved neuronal-specific functions, and whose misregulation
is linked to autism22–24. Despite their involvement in
protein–protein interactions23,25, the detection of protein varia-
tion associated with differential microexon inclusion using pro-
teomics is currently challenging.
Sequencing of ribosome-protected RNA fragments, i.e., ribo-
some profiling, provides information on the messengers being
translated in a cell. In particular, it allows the identification of
multiple translated open-reading frames (ORFs) in the same gene
and the discovery of novel translated genes26–29. However, ribo-
some profiling studies have been mainly oriented to gene-level
analysis26,28,30. Recently, reads from ribosome profiling have been
mapped across the exon–exon junctions of alternative splicing
events31, suggesting that alternative splicing products may be
engaged by ribosomes and potentially translated to produce dif-
ferent protein isoforms. A potential limitation of that approach is
that ribosomal profiling reads also contain signals from native,
non-ribosomal RNA–protein complexes32; hence, the mapping of
ribosome reads to these regions may not necessarily be indicative
of active translation. In addition, ribosome activity is associated
with signal periodicity and uniformity along open-reading
frames33, which has not yet been tested in relation to transcript
isoforms and alternative splicing. Thus, the extent to which
alternative splicing, and in particular microexon inclusion, leads to
the translation of alternative ORFs remains largely unknown.
In this paper, we describe ORQAS (ORF quantification pipe-
line for alternative splicing), a method to quantify translation
abundance at individual transcript level from ribosome profiling
by taking into account ribosome signal periodicity and uniformity
per isoform. We validate the translation quantification of iso-
forms using independent data from polysomal fractions and
proteomics. We further find a concordance between differential
splicing and translation and obtain evidence for the differential
translation of microexons that is conserved between human and
mouse. ORQAS provides a powerful strategy to study the impacts
of differential RNA processing in translation.
Results
Translation abundance estimation at isoform level with
ORQAS. We developed ORQAS (ORF quantification pipeline for
alternative splicing) for the estimation of isoform-specific trans-
lation abundance and to investigate the impact of differential
splicing on translation (Fig. 1a) (see the “Methods” section).
ORQAS quantifies the abundance of open-reading frames (ORFs)
in RNA space from RNA sequencing (RNA-seq) in transcript per
million (TPM) units, and assigns ribosome-sequencing (Ribo-
seq) reads to the same ORFs using RiboMap34. After the
assignment of Ribo-seq reads to isoform-specific ORFs, ORQAS
only considers ORFs with at least ten Ribo-seq reads after pooling
replicates, and with average RNA-seq abundance greater than 0.1
in TPM units. ORQAS then calculates for each of these ORFs two
essential metrics to determine their potential translation: uni-
formity, calculated as a proportion of the maximum entropy of
the read distribution, and the 3nt periodicity along the ORF. The
translation abundance of each ORF is then calculated in ORF per
million (OPM) units. These abundances are then used to study
the impact of differential splicing on translation (see the
“Methods” section).
We used ORQAS to analyze Ribo-seq and matched RNA-seq
data from human and mouse glia and glioma30, mouse
hippocampus35, and mouse embryonic stem cells36 (Supplemen-
tary Table 1). To determine which values of uniformity and
periodicity are indicative of an isoform being translated, we
selected as positive controls 929 human genes with a single
annotated ORF and with evidence of protein expression from
mass spectrometry (MS), immunohistochemistry (IHC), and
Uniprot in all 37 tissues available in the Human Protein Atlas
(THPA)37. For the mouse samples, the positive controls were 802
genes with one-to-one orthology with the human positive
controls. We considered the translation of those ORFs within
90% of the periodicity and uniformity distribution of these
positive controls (Fig. 1b, Supplementary Fig. 1). This produced a
total of 20,709–20,785 translated ORFs in human, and
13,019–17,515 in mouse (Supplementary Table 2).
To determine the robustness of our filter on RNA abundance,
we considered other cutoffs, but the results did not change
significantly after removing cases below 1 TPM (Supplementary
Fig. 2). As a further quality control, we considered the proportion
of isoforms with low or no RNA expression that fell inside our
periodicity and uniformity cutoffs and found only 0.7–0.9%
across the human samples and 0.1–1.5% in the mouse samples
(Supplementary Table 3). To show that ORQAS provides an
advantage over simply quantifying isoforms from Ribo-seq, we
analyzed 1005 genes with one single annotated ORF not included
in the list of positive controls used above, and calculated the
proportion of cases that showed evidence of protein expression
from IHC experiments from THPA. We observed that cases that
did not pass ORQAS thresholds generally lacked protein evidence
(Fig. 1c). A similar analysis with all genome-wide predictions, not
including any single-ORF gene, also showed that genes with
translated isoforms are more frequently validated at all levels of
protein expression, and that the majority (96%) of genes with
translated ORFs showed some evidence of protein expression
from MS, IHC, or Uniprot (Supplementary Fig. 3a, b). To further
validate the selection of these cutoffs, we considered genes with
specific protein expression in the brain, heart, intestine, liver,
spleen, or testis. We found that ORQAS predicts in glia a higher
proportion of translated ORFs in the subset of brain-specific
genes compared with the other tissues (Supplementary Fig. 3c).
ORQAS predicted that a large fraction of the expressed
protein-coding genes had multiple translated isoforms:
52.3–54.9% of the genes in human and 29.1–35.9% in mouse
(Supplementary Fig. 4). Overall, the majority of translated
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Fig. 1 Estimation of translated isoforms. a Diagram of the ORQAS pipeline. b Uniformity (x-axis) and periodicity (y-axis) for all tested ORFs with RNA
expression TPM >0.1 and ≥10 Ribo-seq reads assigned (yellow) from human glia (n= 28,427). Uniformity is the percentage of maximum entropy, and
periodicity is measured in the first annotated frame. In blue, single-ORF genes with protein expression in 37 tissues from the Human Protein Atlas (THPA).
Other samples are shown in Supplementary Fig. 1. c ORQAS predictions in human glia for 1005 single-ORF genes. The plot shows the protein expression
from immunohistochemistry (IHC) experiments in human cortex from THPA for cases without enough RNA expression (Not evaluated n= 468), cases
that do not pass the filters of uniformity and periodicity (Not-translated n= 176), and those predicted to be translated (n= 361). d Number of ORFs
translated per sample, according to whether the ORF is encoded by a single-ORF gene (Single), the most abundant isoform according to RNA-seq (Main
isoform), the second most abundant (Secondary isoform), or by any of the remaining isoforms (Other isoforms). Tested ORFs that are not-translated are
depicted in gray (Not-translated). e Average density of Ribo-seq reads along ORFs in the single-ORF genes from above, in ORFs from the most abundant
isoform according to RNA-seq, and in the second most abundant isoform. f Number of ORFs translated per gene in human glia (hsa glia) according to
ORQAS (orange) and ORFquant (yellow) predictions. Other samples are shown in Supplementary Fig 6. g Correlation between average ORF abundance in
ribosome space for human glia (hsa glia n= 53,403) in ORFs per million (OPM) by ORQAS and P sites per nucleotide per million (P sites pNpM) by
ORFquant, indicating whether each ORF is predicted only by ORQAS (orange) or by ORFquant (yellow), by both (blue), or none of them (gray). Other
samples are shown in Supplementary Fig 8. h Distribution of the average RNA expression in human glia (has glia n= 30,035) in TPM for ORFs predicted
only by ORQAS (orange), by ORFquant (yellow) or by both (blue). Other samples are shown in Supplementary Fig. 9.
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isoforms corresponded to either single-isoform genes or to the
isoform with the highest expression in a sample (main isoform)
(Fig. 1d). However, from those genes with multiple isoforms
expressed at the RNA level, 3,471–3,570 (52.6–55.5%) of genes in
human and 577–898 (27.6–34%) in mouse had an alternative
isoform translated (Fig. 1d). From all translated isoforms,
47.3–49.2% in human, and 28.3–34.9% in mouse, correspond to
alternative isoforms (secondary or other isoform, Fig. 1d). In
genes with multiple isoforms, the main isoform showed the
highest average Ribo-seq coverage compared with secondary
isoforms, albeit not as high as for the single-ORF genes used as
positive controls (Fig. 1e). In addition, the periodicity of the
translated isoforms was uniform across the ORFs (Supplementary
Fig. 5).
We compared ORQAS with ORFquant38, another method to
calculate translation at isoform level from Ribo-seq. We run
ORFquant on the same samples analyzed with ORQAS. Looking at
the annotated ORFs, ORQAS detected more genes with multiple
ORFs consistently across all samples tested (Fig. 1f, Supplementary
Fig. 6). Calculating the level of agreement between both methods
with a Jaccard index, there was a higher level of agreement at gene
level than at isoform level (Supplementary Fig. 7). We also
compared the translation abundance provided by both methods.
ORFquant abundance is based on the normalized number of P
sites per nucleotide, whereas ORQAS provides an abundance in
ORFs per million (OPM), akin to TPM units. We observed in
general a good correlation of the abundance values for ORFs
predicted to be translated by both methods (Fig. 1g, Supplemen-
tary Fig. 8). However, many isoforms that did not pass ORQAS
read-count filter still showed high abundance according to
ORFquant. ORFs predicted only by ORFquant turned out to have
low or no RNA-seq expression (Fig. 1h, Supplementary Fig. 9).
ORQAS discriminates translation at isoform level. To validate
the translation predictions by ORQAS at isoform level, we
compared the results from Ribo-seq with the RNA abundances
measured from polysomal fractions in the same human neuronal
and embryonic stem cell samples39. ORQAS predicted 27,552
translated isoforms in stem cells, and 25,034 in neurons (Sup-
plementary Fig. 10a). To control for the fact that monosomes can
contain translating short mRNAs40 (Supplementary Fig. 10b, c),
we separated isoforms in three different length ranges. We found
that translated isoforms predicted by ORQAS were enriched in
polysomal fractions at all length ranges (Fig. 2a, Supplementary
Fig. 10d). In contrast, isoforms with RNA expression, but not
predicted to be translated with ORQAS, were enriched in
monosomal fractions (Fig. 2a). This provides support for our
predictions and is also consistent with a small proportion of our
predicted translated isoforms to be associated with nonsense-
mediated decay (NMD) targets, which are generally associated
with monosomes41.
Cross-species conservation is a strong indicator of stable
protein production42. We thus decided to test the conservation of
our translated isoforms in human and mouse, using glia and
glioma samples available for both species. To this end, we used an
optimization method to determine the human–mouse protein
isoform pairs most likely to be functional orthologs (Fig. 2b, see
the “Methods” section). From 15,824 human–mouse 1-to-1 gene
orthologs, we identified 18,574 human–mouse protein isoform
pairs, and 7112 (64%) of the 1-to-1 gene orthologs had more than
one such isoform pair. These 18,574 protein pairs represent
orthologous protein isoform pairs. We found that orthologous
isoform pairs were significantly enriched in translated isoforms in
both species (Fisher’s test p-value <2.2e–16 in all datasets)
(Fig. 2c), providing further support for our predictions.
To perform an additional validation of our findings, we
considered isoform-specific regions (Fig. 3a), since evidence
mapped to these regions can then be unequivocally assigned to
the isoform (see Supplementary Figs. 11 and 12 for specific
examples). We defined two types of isoform-specific regions. One
type was defined in terms of isoform-specific nucleotide
sequences, i.e., continuous nucleotide stretches that are only
included in an isoform. From the annotation, we were able to
identify 34,554 isoforms with such regions in human and 29,447
in mouse. We found that translated isoforms had a significantly
higher density of Ribo-seq reads per nucleotide in those regions
than non-translated isoforms (Fig. 3b, Supplementary Fig. 13a).
In addition, unique sequence regions harbored more uniquely
mapping Ribo-seq reads in translated isoforms compared with
non-translated ones (Fig. 3c, Supplementary Fig. 13b). Overall, we
were able to validate 56–80% of the isoform-specific sequence
regions.
To be able to validate our predictions using P sites and peptides
from MS experiments, we additionally considered isoform-
specific ORF regions (Fig. 3a). These were defined as sequences
that may or may not be shared between isoforms, but had a
specific frame in each isoform, so that peptides from MS
experiments can be unequivocally mapped on these regions.
From the annotation, we found in total 44,299 isoforms with
specific ORF regions in human and 34,329 in mouse. These
included the 34,554 and 29,447 isoforms calculated before with
ORFs from isoform-specific sequences in human and mouse,
respectively: hence, there were 9745 and 4882 isoforms in the
human and mouse annotations, respectively, that did not have
differences in sequence, but had different overlapping ORFs. We
found that translated isoforms had a significantly higher density
of P sites in isoform-specific ORFs (Fig. 3d, Supplementary
Fig. 13c). We further used peptides from MS experiments42 to
validate our predictions. Overall, we validated more isoforms
predicted as translated compared with those predicted as not-
translated (Fig. 3e). The rate of validation decreased with the
region length, as expected for MS experiments41. On the other
hand, the proportion of predictions validated with peptides
increased using increasing cutoffs for RNA expression (Supple-
mentary Fig. 13d). Overall, we were able to validate 48–73% of the
isoform-specific ORFs tested.
In summary, from all the protein-coding transcript isoforms
considered from the annotation (84,024 in human and 48,928 in
mouse), 58–59% in human and 63–65% in mouse showed RNA
expression >0.1 TPM (Supplementary Table 4, translated iso-
forms are available in Supplementary Data 1). From these
expressed isoforms, about 40% in human and 41–54% in mouse
were predicted to be translated by ORQAS, and 23–43% were
validated using independent data, including conservation (Fig. 3f).
Furthermore, 60% of the alternative isoforms predicted as
translated had independent evidence of translation, and these
corresponded to approximately 10% of all the annotated
alternative isoforms in human and mouse (Supplementary
Fig. 13e). Our analyses thus indicate that alternative transcript
isoforms are often translated into protein, although they represent
a small fraction of all expressed transcripts.
Conserved impact of differential splicing on translation. Dif-
ferential splicing is often assumed to lead to a measurable dif-
ference in protein production. However, this has only been shown
for a limited number of cases16. We addressed this question at
genome scale using our more sensitive approach based on Ribo-
seq. We used SUPPA43,44 to obtain 37,676 alternative splicing
events in human and 17,339 in mouse that covered protein-
coding regions (see the “Methods” section, all alternative splicing
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events are available in Supplementary Data 2-4). Using the same
SUPPA engine to convert isoform abundances to event inclusion
values43,44, we calculated a relative abundance (RA), defined as
the proportion of translation abundance of the isoforms given by
ORQAS that is explained by a particular alternative splicing event
(Fig. 4a). Accordingly, in analogy to a relative inclusion change
(ΔPSI) in RNA space, we were able to measure the relative dif-
ferences in ribosome space due to the inclusion or exclusion of
particular alternative exons, or ΔRA.
Comparing the glia and glioma samples in human, we found
856 events with a significant change in RNA splicing (|ΔPSI | >
0.1 and p-value < 0.05, as calculated by SUPPA), and 590 events
with significant differential translation (|ΔRA | > 0.1 and p-value
< 0.05, as calculated by SUPPA), with a significant overlap of 363
events between them (Jaccard index z score= 89.386 compared
with the Jaccard index distribution of the overlaps from
1000 subsample sets of the same size) (Supplementary Fig. 14a).
Similarly, in mouse, we found an overlap of 179 events (Jaccard
index z score= 65.326) between 471 events with a significant
change in RNA splicing (|ΔPSI | > 0.1 and p-value < 0.05, as
calculated by SUPPA) and 240 with significant change in
translation (|ΔRA | > 0.1 and p-value < 0.05, as calculated by
SUPPA) (Supplementary Fig. 14b).
We observed a concordance in the direction and magnitude of
the change in significant events in RNA and ribosome space in
human (Pearson R= 0.9904, p-value= 5.309e–312) and mouse
(Pearson R= 0.9937, p-value= 2.113e–170), and this concor-
dance was greater than for the rest of events (Fig. 4b,
Supplementary Fig. 14c). We further observed a similar
proportion of event types changing significantly in RNA and
ribosome space, with an enrichment of exon-skipping events in
human (Fig. 4c) and mouse (Supplementary Fig. 14d). To
investigate the nature of these enriched cases, we considered very
short alternative exons, or microexons, which are known to be
differentially included in brain cells23,45. We tested the inclusion
properties of alternative exons in RNA and ribosome space in our
samples. We observed that alternative exons show less inclusion
in glioma compared with glia at lengths 51nt or below, with a
stronger pattern below 28nt, which are the two previously
employed length cutoffs to define microexons (Supplementary
Fig. 14e)23,45.
Microexons, defined here as exons of length 51nt or less, were
enriched in the events with significant changes in RNA-seq
(Fisher’s test p-value 0.01125200 in human, 1.231482e–10 in
mouse) and in Ribo-seq (Fisher’s test p-values 0.03917744 in
human, 1.049473e–06 in mouse). This enrichment was also
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Fig. 2 Validation of predictions. a We show the distribution of the relative abundance in high polysome (left panels) and monosome (right panels)
fractions of human embryonic stem cells (ESC) for translated isoforms and for isoforms with RNA expression (TPM > 0.1) but predicted as not-translated.
The plot shows the results for three different ORF lengths: 200–1000nt (high polysome Wilcoxon test p-value 7.2e–67, translated n= 18,056 and not-
translated n=9397, and monosome Wilcoxon test p-value 2.3e–77, translated n= 15,023 and not-translated n=8277), 1001–10000nt (high polysome
Wilcoxon test p-value 2.5e–242, translated n= 19,169 and not-translated n= 3813, and monosome Wilcoxon test p-value 1.1e–94, translated n= 16,002
and not-translated n= 3179), and longer than 10000nt (high polysome Wilcoxon test p-value 5.1e–10, translated n= 200 and not-translated n= 69, and
monosome Wilcoxon test p-vaue 5e–06, translated n= 178 and not-translated n= 66). The results for neuronal cells are given in Supplementary Fig. 3.
Box boundaries correspond to the first and the third quartiles, the median is indicated by a thick black line, top and bottom whiskers extend up to 1.5 times
the interquartile range to the highest and smallest values, respectively, and outliers are indicated as black dots. b Cross-species conservation of protein
isoforms. Protein isoforms from each 1-to-1 orthologous gene pair are compared, and candidate orthologous pairs are assigned using an optimization
approach (see the “Methods” section). c For the set of ORFs encoding a human–mouse orthologous protein pair (orthologous) and for those encoding
proteins without an orthologous pair in mouse (non-orthologous), we plot the percentages that are predicted to be translated (translated) and the ones
with RNA expression (TPM > 0.1) but predicted as not-translated (not-translated). We show here the results for human glia (Fisher’s test p-value=
1.41e–140, orthologous n= 12,801 and non-orthologous n= 17,111) and glioma (Fisher’s test sp-value= 3.63e–85, orthologous n= 12,453 and non-
orthologous n= 16,278), and for mouse glia (Fisher’s test p-value= 1.143e–130, orthologous n= 12,792 and non-orthologous n= 7356) and glioma
(Fisher’s test p-value= 7.462e–53, orthologous n= 12,015 and non-orthologous n= 5905). Other mouse samples are shown in Supplementary Fig. 10e.
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present if microexons were defined to be of length <28nt: Glia vs
Glioma in human (Fisher’s test p-value for RNA-seq 5.435e–13,
for Ribo-seq 1.17e–09), Glia vs Glioma in mouse (Fisher’s test p-
value for RNA-seq 7.47e–14, for Ribo-seq 3.194e–06), and
Human ESC vs differentiated neurons (Fisher’s test p-value for
RNA-seq 2.725e–08, for Ribo-seq 6.768e–06). Moreover, micro-
exons were enriched in events decreasing inclusion in glioma
compared with glia in both human (Fisher’s test p-values
1.382e–12 for RNA-seq and 5.602e–10 for Ribo-seq) (Fig. 4d)
and mouse (Fisher’s test p-values 6.386e–16 for RNA-seq and
3.446e–06 for Ribo-seq) (Supplementary Fig. 14f). We repeated
the same analysis using data from human neuronal differentia-
tion39 and found that microexons were also enriched in the
comparison between embryonic stem cells and neuronal cells in
terms of RNA splicing and translation (Fisher’s test p-values
8.435e–06 for RNA-seq and 6.597e–05 for Ribo-seq) (Supple-
mentary Fig. 14g). Furthermore, using RNA sequencing from
polysome fractions from the same stem cell and neuronal
samples, we were able to validate the change in inclusion patterns
of microexons under the same conditions (Fig. 4e).
We compared the capacity of ORQAS and ORFquant to detect
translation of microexon-containing ORFs. In general, we
observed that isoforms predicted by ORQAS included more
cases with short (<51nt) and very short (<29nt) isoform-specific
regions than ORFquant (Supplementary Fig. 15), hence providing
a greater potential to identify translating microexons. Indeed,
ORQAS identified more microexons than ORFquant in all tested
samples (Fig. 4f). We also performed a comparison with
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previously detected alternative splicing events using a direct
mapping of Ribo-seq reads to the exon–exon junctions31. While
there was a high overlap for exons longer than 51nt, ORQAS
identified more microexons (Fig. 4g).
Our results provide evidence that differential splicing leads to a
qualitative and quantitative change in the protein products from a
gene locus. These results are also consistent with a functional
relevance of the inclusion of microexons in protein-coding
transcripts in neuronal differentiation and their inclusion loss in
brain-related disorders22,23. Our analyses also highlight the
strength of ORQAS in detecting these microexons compared
with other alternative methods.
To further test the relevance of our findings, we considered a
set of 1487 alternative exons conserved between human and
mouse (Fig. 5a). A high proportion of them changed in the same
direction between glia and glioma (66% in RNA-seq and 78% in
Ribo-seq). Moreover, we observed that among the events with
concordant changes between both species, there was an enrich-
ment of microexons, with a significant trend toward less inclusion
in glioma (Fisher’s test p-values 5.389e–05 for RNA-seq and
5.521e–04 for Ribo-seq) (Fig. 5b). Furthermore, there was a
correlation between the changes in ribosome space in human and
mouse (Fig. 5c).
Among the microexons with a differential pattern of splicing
and translation, we identified one in the gene GOPC (Fig. 5d),
which was previously linked to glioblastoma46, and one in the
gene CERS6 (Fig. 5d), which has been associated with
chemotherapy resistance47. To test further the potential relevance
of the identified microexons with conserved differential pattern,
we calculated their RNA splicing inclusion patterns across other
normal and tumor brain samples. In particular, we analyzed
samples from glioblastoma multiforme (GBM) from TCGA48,
neuroblastoma (NB) from TARGET49 (Fig. 5e), and samples
from the cortex and hippocampus from GTEX50. Microexons
with a conserved impact on translation recapitulate the pattern of
decreased inclusion in GBM compared with the postmortem
normal brain regions (Fig. 5e). Differentially translated micro-
exons may explain tissue differentiation as well as tumor-specific
properties, as they separate out healthy tissues and tumor types
(Supplementary Fig. 16a). In contrast, conserved microexons are
clearly more prevalent in differentiated brain tissues than in
tumor samples (Supplementary Fig. 16b).
Discussion
We have described ORQAS (https://github.com/comprna/orqas),
a method to obtain transcript abundance estimates at isoform
level in ribosome space, to identify multiple protein products
from a gene, and to investigate differential translation associated
with alternative splicing and differential transcript usage between
conditions. Our approach presents several novelties and advan-
tages over other methods31,34,38,39: (i) filtering based on the
periodicity and uniformity of the Ribo-seq reads improves the
identification of translated isoforms, (ii) the use of RNA expres-
sion to guide the translation abundance estimation avoids many
potential false positives, (iii) our description in terms of isoforms
allows the identification of more translated alternative isoforms
and, in particular, microexons compared with other methods, (iv)
our validation using isoform-specific regions, regardless of whe-
ther these regions could be encoded into a standard alternative
splicing event, provides a more general validation of the impact of
differential splicing on translation, and (v) ORQAS provides
isoform abundance estimates in ribosome space that can be
reused by other tools, like SUPPA. Our analyses were limited to
transcripts and ORFs present in the annotation, but it is possible
to adapt our method to work with new isoforms once their
sequences and ORFs are predicted from the RNA-sequencing
data. We also did not consider the contribution from upstream
ORFs (uORFs), which can also be potentially detected based on
abundance and periodicity51.
We estimated that in total about 40–50% of the protein-coding
isoforms with RNA expression showed some evidence of trans-
lation, and that around 20,700 proteins are produced in human
and 13,000–17,500 in mouse in the tested conditions. In addition,
about 5700–5800 genes in human and 2600–3900 in mouse
produce more than one protein in those conditions. These esti-
mates are considerably lower than what is generally predicted
from RNA expression8. This may be explained by the limited
coverage of Ribo-seq reads, but may also be due to the fact that
RNA-seq artificially amplifies fragments of unproductive RNAs,
leading to many false positives. Nonetheless, our data indicate
that many more ORFs are translated in a given sample than what
is detectable by current proteomics methods, and that the number
of detected translated ORFs is close to estimates obtained using a
combination of proteomics and sequence conservation42.
Importantly, we found that multiple ORFs are translated from the
same gene and at different abundances across conditions.
Around 40% of the events detected with differential RNA
splicing showed consistent measurable changes in Ribo-seq in the
same direction, which supports the notion that changes in RNA
processing have a widespread impact on the translation of ORFs
from a gene. In particular, we found that a pattern of decreased
inclusion of microexons in glioma with respect to normal brain
samples is recapitulated at the translation level, providing in vivo
evidence that the splicing changes in microexons have an impact
on protein production. Microexon inclusion is a hallmark of
Fig. 3 Validation with isoform-specific regions. a Isoform-specific sequence regions (pink) are defined as the parts of an isoform ORF not present in any
other isoform from the same gene. Isoform-specific ORFs (green) are defined as a region shared between two isoforms, but with a different frame in each
isoform. b Density of Ribo-seq reads per nucleotide over the isoform-specific sequence regions for isoforms with ≥1 unique mapping read for mouse glia
(mmu glia n= 13,541) and hippocampus (mmu hipp n= 18,015) samples. Distributions are given for predicted translated isoforms, for isoforms that did not
pass the threshold of uniformity and periodicity (not-translated), and for the isoforms with low expression (TPM < 0.1) (not evaluated). Other samples are
shown in Supplementary Fig. 13a. Box boundaries correspond to the first and the third quartiles, the median is indicated by a thick black line, top and
bottom whiskers extend up to 1.5 times the interquartile range to the highest and smallest values, respectively, and outliers are indicated as black dots.
c Percentage of regions with ≥10 uniquely mapping Ribo-seq reads in isoform-specific sequence regions, for mouse glia (mmu glia) and hippocampus
(mmu hipp) samples. Other samples are shown in Supplementary Fig. 13b. d Density of Ribo-seq reads per nucleotide over the specific ORF regions for
isoforms with ≥1 P-site position count, for mouse glia (mmu glia n= 1143) and hippocampus (mmu hipp n= 1445) samples. Other samples are shown in
Supplementary Fig. 13c. e Percentage of sequence- and ORF-specific regions with one or more mass-spectrometry peptides, separated according to region
length, for mouse glia (mmu glia) and hippocampus (mmu hipp) samples. Box boundaries correspond to the first and the third quartiles, the median is
indicated by a thick black line, top and bottom whiskers extend up to 1.5 times the interquartile range to the highest and smallest values, respectively, and
outliers are indicated as black dots. f Proportion of isoforms expressed (TPM > 0.1) predicted to be translated and validated with one or more sources of
evidence: conservation, unique regions, and counts per base or peptides in specific ORF regions.
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neuronal differentiation22,23,44, and glia partly recapitulates the
pattern of microexon inclusion found in neurons23. The
decreased inclusion of microexons observed in glioma suggests a
dedifferentiation pattern similar to the one previously described
before for other tumors52, but could also be indicative of a dif-
ference in the content of neuronal cells in the samples compared.
In either case, the evolutionary conservation of the change at
RNA expression and protein production indicates a conserved
functional program in these samples.
Our capacity to predict RNA splicing variations from RNA-seq
data currently exceeds our power to evaluate the significance
of those events regarding protein production with current
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proteomics technologies53. Despite this limitation, mass spec-
trometry can show for a small number of cases that splicing
changes impact the abundance of proteins produced by a gene16.
Our findings are in agreement with these results, and moreover
overcome current limitations to determine genome-wide impacts
of RNA-processing changes on protein production. Furthermore,
our analyses indicate that the majority of translated alternative
isoforms shows less than 25% variation in length with respect to
the most highly expressed isoform, suggesting that for most part,
the functional impacts from alternative splicing are mediated by
slight modifications in the protein sequences25, rather than
through the production of essentially different proteins. In
summary, ORQAS leverages ribosome profiling to provide a
genome-wide coverage of genes and transcript isoforms, and
allow a more effective testing of the impacts of splicing on protein
production, as well as the identification and validation of multiple
proteins from the same gene locus.
Methods
Preprocessing of RNA- and Ribo-seq datasets. RNA- and Ribo-seq datasets
were downloaded from Gene Expression Omnibus (GEO) for the following sam-
ples: normal glia and glioma from human and mouse (GSE51424)30, mouse hip-
pocampus (GSE72064)35, mouse embryonic stem cells (GSE89011)36, and three
steps of forebrain neuronal differentiation in human (GSE100007)39. Adapters in
RNA- and Ribo-seq datasets were trimmed using cutadapt v.1.12 with additional
quality filters for RNA-seq (−q= 30). We further discarded reads that mapped to
annotated rRNAs and tRNAs. The remaining reads in RNA- and Ribo-seq datasets
were filtered by length (≥26 nucleotides).
Quantification of transcripts and open-reading frames. We used the Ensembl
annotation v85 for human (hg19) (GRCh37.85) and mouse (mm10) (GRCm38.85)
by removing pseudogenes, short isoforms (<200 nt), and annotated isoforms with
incomplete 5′ or 3′ regions. For the analysis of RNA-seq data, we used Salmon
v0.7.254 to quantify transcript abundances in transcripts per million (TPM) units
using the annotation of unique open-reading frames (ORFs). To quantify coding
sequences (CDS) at the isoform level with the Ribo-seq data, we applied a modified
version of Ribomap34 that uses the RNA-seq abundance as priors for the opti-
mization algorithm to distribute Ribo-seq reads among the different isoforms. As
default, Ribomap uses the RNA-seq reads aligned to the transcriptome sequences
with STAR55. Instead, we provided a direct quantification of the ORFs with RNA-
seq using Salmon, to be used as priors by RiboMap. We calculated the translation
abundances of each ORF based on Ribo-seq reads in ORFs per million (OPM)
units, similar to TPM units, but for ORFs instead of complete transcripts and using
Ribo-seq reads. OPM values are calculated as follows:
OPMi ¼ 106
ni=liP
j nj=lj
ð1Þ
where ni is the estimated Ribo-seq counts in ORF i and li is the effective length of
the same ORF.
We performed benchmarking against ORFquant38 with default parameters,
considering only the ORFs in the annotation with the above-mentioned filters.
Identification of translated isoform-coding sequences. We identified actively
translated ORFs by calculating two parameters’ read periodicity and read uni-
formity33. The periodicity is based on the distribution of the reads in the annotated
frame and the two alternative ones. In order to calculate the read periodicity, we
previously computed the position of the P site, corresponding to the tRNA-binding
site in the ribosome complex. This was obtained by calculating the distance
between annotated ATG start codons and the leftmost position covered by Ribo-
Seq reads, for each read length. The uniformity was measured as the proportion of
maximum entropy (PME) defined by the distribution of reads along the ORF
H Xð Þ ¼
Xn
i¼1
Ni
N
 
 log2
Ni
N
 
ð2Þ
PME ¼ HðXÞ
maxðHÞ ð3Þ
where N represents the total number of reads, Ni is the number of reads in each
region i, and max(H) is the entropy assuming that the reads are equally distributed
across the ORF. The maximum value is 1 and indicates a completely even dis-
tribution of reads across codons. These values were obtained for each sample by
pooling the replicates and only considering ORFs with ten or more assigned Ribo-
seq reads, and with RNA-seq abundance TPM > 0.1.
Polysomal fraction analysis. We used RNA-seq from high polysomal, low
polysomal, and monosomal fractions from embryonic stem cells and neuronal cell
culture in human (GSE100007)39 to quantify isoforms with Salmon54. Only ORFs
from protein-coding isoforms were used for quantification. For each isoform, we
calculated the polysomal relative abundance as before17 by dividing the abundance
in each polysomal fraction in TPM units, by the sum of abundances in (high and
low) polysomes and monosomes.
Validation of isoform-specific regions. We defined two different types of
isoform-specific regions that were analyzed differently. Isoform-specific sequences
are regions with a unique nucleotide sequence among the isoforms of the same
gene. Isoform-specific ORFs are defined as regions that will give rise to different
amino-acid sequences within the proteins of the same gene, either because of the
presence of isoform-specific sequences or frame-shifted common sequences
(Fig. 3a). According to the annotation, we identified 34553 isoforms containing
isoform-specific sequences in human and 29,447 in mouse, and 44,298 isoforms
containing isoform-specific ORFs in human and 34,329 in mouse. For the vali-
dation of isoform-specific sequences, we considered uniquely mapping Ribo-seq
reads from the STAR output falling entirely inside these regions or in the junction
of the specific sequence with the common region. Read densities inside those
regions were calculated as the total number of uniquely mapping reads in the
region divided by the length of the isoform-specific sequence. The validation of
isoform-specific ORFs instead was performed using the profiles of counts in each
base of the ORF, considering the expected position of the P site. For isoform-
specific ORFs, the read densities were established as the total number of counts in
the region divided by the length in nucleotides of the isoform-specific ORFs.
Proteomics evidence in translated isoform-coding sequences. We mined the
proteomics database PRIDE56 to search for peptide matches to ORFs. We only
considered peptide datasets from mouse corresponding to tissues analyzed in this
study: brain (PRD000010, PXD000349, and PXD001786), hippocampus
(PRD000363, PXD000311, and PXD001135), and embryonic cell lines
(PRD000522). This corresponded to a total of 328,200 peptides. We searched for
peptide matches in translated ORFs and only kept peptides that had one perfect
match to an ORF and did not have a match with 0, 1, or 2 amino- acid mismatches
to any other annotated ORF isoform from the same or different genes.
Differential inclusion of events in RNA and ribsome space. We used
SUPPA43,44 to generate alternative splicing events defined from protein-coding
transcripts and covering the annotated ORFs with generateEvents subcommand.
The relative inclusion of an event was calculated as a Percent Spliced In (PSI) value
with SUPPA in terms of the transcript abundances (in TPM units) calculated from
RNA-seq and in terms of the ORF abundances (in OPM units) calculated from
Ribo-seq with psiPerEvent subcommand (Fig. 4a). The test for significant differ-
ential inclusion of the events was applied in the same way for both cases by testing
the difference between the observed change between conditions and the observed
change between replicates using diffSplice subcommand44.
Calculation of orthologous isoforms. We considered the set of 1-to-1 orthologous
genes between human and mouse from Ensembl (v85)57. For each pair of orthologous
genes, we calculated all possible pairwise global alignments between the human and
mouse proteins encoded by these genes using MUSCLE58. For each alignment, we
defined a score as the fraction of amino-acid matches over the total length of the global
alignment and kept only protein pairs with score >= 0.8. From all the remaining
protein pairs in each orthologous gene pair, we selected the best human–mouse
protein pairs using a symmetric version of the stable marriage algorithm59.
Comparison with normal and tumor tissues. We downloaded the transcriptome
(GRCh38) TPM values calculated with RSEM60 from the XENA browser (https://
xenabrowser.net/datapages/) for GTEX50, TARGET49, and TCGA48. PSI values for
the alternative splicing events in human were calculated with SUPPA43,44 from
these TPM values, and the coordinates of the events were transformed to GRCh37
(hg19). We used 105 cortex and 84 hippocampus samples from GTEX, 171 glio-
blastoma multiforme samples from TCGA, and 162 neuroblastoma samples from
TCGA to analyze the PSI values of the identified translated microexons.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
Predicted translated isoforms in the samples analyzed together with their validation using
independent datasets are provided in Supplementary Data 1. All calculated alternative
splicing events in RNA and ribosome space with annotations for microexons and
orthology are provided in Supplementary Data 2 (comparison between human glia and
glioma), Supplementary Data 3 (comparison between human ESCs and neuronal cells),
and Supplementary Data 4 (comparison between mouse glia and glioma). All data are
available from the corresponding author upon reasonable request.
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Code availability
ORQAS pipeline is available at https://github.com/comprna/ORQAS/.
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